┌──────────────────────────────────────────────────────────────┐ RECORD TYPE ......... SUBJECT FILE SUBJECT TYPE ........ ORG FILE OPENED ......... 2026-07-05 17:23 UTC APPEARANCES ......... 13 ANNOTATIONS KNOWN ALIASES ....... 1 └──────────────────────────────────────────────────────────────┘
Paroxetine
ALSO APPEARS AS
- Paroxetine
APPEARS IN THE MARGINS OF
- Paroxetine Prescriptions for Adolescents (2001-2015) After Study 329 Publication
Study 329 was a clinical trial of paroxetine and imipramine in adolescents with major depression, funded by SmithKline Beecham and published in 2001. The original publication by Keller and colleagues …
- Study 329 Adverse Event Data Exclusion and FDA Disclosure
Study 329, a clinical trial of paroxetine (Paxil) in adolescents with major depressive disorder, was conducted from 1994 to 1998 and initially published in 2001 by Keller and colleagues. This original…
- Paroxetine Off-Label Adolescent Use Data Prior to 2015 Reanalysis
The question concerns the availability of publicly accessible sales volume or prescription data specifically for off-label paroxetine use in adolescents prior to the 2015 reanalysis of Study 329. Whil…
- Paroxetine Prescription Rates for Adolescents (2001-2015)
This dossier investigates the annual prescription numbers for paroxetine to adolescents in the US and other major markets between 2001 and 2015. While a declassified FDA statement from March 2004 advi…
- Medical Guidance on Paroxetine for Adolescents and Study 329 Reference (2001-2015)
Following the 2001 publication of Study 329, an influential clinical trial on the antidepressant paroxetine (Paxil/Seroxat) for adolescent depression, questions arose regarding its efficacy and safety…
- Martin Keller's Role and Statements in Study 329 Paroxetine Trial
Study 329 was a clinical trial conducted from 1994 to 1998 to evaluate the efficacy of paroxetine (Paxil/Seroxat), an SSRI antidepressant, for major depressive disorder in adolescents aged 12-18 [2, 6…
- Study 329 RIAT Reanalysis: Previously Unreported Adverse Events
Study 329 was an industry-sponsored clinical trial of paroxetine (Paxil/Seroxat) for adolescent depression, originally published in 2001. The original publication claimed the drug was generally well-t…
- Study 329: Contents of Appendix H and GSK's Data Provision to RIAT
Study 329 was a clinical trial sponsored by SmithKline Beecham (now GSK) investigating paroxetine in adolescents with depression. The original published results by Keller et al. in 2001 were subsequen…
- FDA Internal Review of Study 329 Adverse Events Pre-RIAT
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, investigating the efficacy and safety of paroxetine and imipramine in adolescents with major…
- SmithKline Beecham Study 329 Adverse Event Data Submission to FDA
Study 329 was a clinical trial of paroxetine (Paxil) in adolescents with major depressive disorder, conducted by SmithKline Beecham (now GlaxoSmithKline - GSK). The original published report in 2001 p…
- Study 329's Impact on Adolescent Antidepressant Prescriptions
Study 329, a clinical trial evaluating paroxetine and imipramine for adolescent major depression, was originally published in 2001, claiming efficacy and safety for paroxetine [1]. This original publi…
- Journal of the American Academy of Child and Adolescent Psychiatry Pre-2015 Ghostwriting Policies
This dossier investigates whether the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), the original publisher of Study 329, had explicit editorial policies or communication…
- Major Medical Journals' Citation of Study 329 in Policy Changes
The clinical trial known as Study 329, which investigated the efficacy of paroxetine in adolescents with major depressive disorder, was conducted from 1994 to 1998 and published in 2001 (Source 6). Th…